Tirzepatide: two receptors, one peptide, and what that changes

One molecule that binds two incretin receptors rather than one. What the GIP arm contributes, why the trial results sit above semaglutide's, and the parts of the panel that are not the scale.

The GIP receptor is the part that is new

Tirzepatide is a single 39-amino-acid peptide that activates both the GLP-1 receptor and the receptor for glucose-dependent insulinotropic polypeptide, the other major incretin hormone. Like semaglutide it carries a fatty-acid chain that binds albumin and buys it a multi-day half-life. Unlike semaglutide it is not a modified GLP-1 at all: the backbone is derived from GIP and engineered to also fit the GLP-1 receptor, which is why it is described as an imbalanced dual agonist rather than two drugs in one.

Established clinical use What GIP agonism adds is still being worked out, which is genuinely interesting rather than a hedge. GIP receptor agonism and GIP receptor antagonism have both produced weight loss in models, which should not be possible if the mechanism were simply additive. The leading explanations involve central GIP receptor signalling affecting food intake and nausea, and effects on adipose tissue nutrient handling. The clinical results are not in doubt; the mechanism behind them partly is.

What SURMOUNT-1 measured

Established clinical use In SURMOUNT-1, published in 2022, adults with obesity and without diabetes lost roughly 15%, 19.5% and 21% of body weight at 5 mg, 10 mg and 15 mg weekly over 72 weeks, against about 3% on placebo. The dose response is the notable part: it did not flatten across the range tested, which is unusual and is why the highest approved amount is where it is.

The trial programme for the diabetes indication reported reductions in HbA1c that exceeded the comparators it was tested against. As with semaglutide, these are means across a wide distribution, they were measured on continued treatment, and weight rather than body composition was the primary endpoint in most arms.

Off-label or community practice Comparisons between tirzepatide and semaglutide are usually made across separate trials with different populations and durations, which is weak evidence for a ranking even when the gap looks large. A head-to-head trial in adults with obesity has since been run and reported greater weight reduction with tirzepatide. That is a stronger basis for the comparison than the cross-trial arithmetic most articles use, and it still says nothing about which is right for a particular person.

Titration, tolerance and the parts of the panel that matter

The modelled half-life is five days against semaglutide's seven, so the level plateaus a little sooner — three to four weeks rather than five — and swings slightly more between weekly injections. The four-week titration interval exists for the same reason it does with semaglutide: stepping up before the previous step has finished accumulating attributes to the new amount what the old one was still doing.

Gastrointestinal effects dominate and follow the titration steps. The monitoring panel the app records is glycaemic and lipid markers plus body composition, and the composition part is the one people skip. Weight alone cannot distinguish a good outcome from a bad one at this rate of loss, which is the whole argument for measuring lean mass rather than inferring it.

Anything severe or persistent — intractable vomiting, dehydration, sustained abdominal pain radiating to the back — is a reason to contact the prescriber rather than to adjust the schedule independently. That is true of the whole class and it is the point at which a page like this one stops being useful.

The curve, the accumulation ratio and the peak-to-trough figures have a page of their own: Tirzepatide half-life and steady state.

The dosing rows the app records

Established clinical use Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Tirzepatide, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• Hematocrit on testosterone therapy
• HbA1c and fasting glucose

Drawbacks and risks the app records

From the app's own entry. Most of these came out of the same trial programme as the efficacy figures above, which is the useful thing about drug data that reached a regulator.

• All GLP-1 class side effects apply
• Muscle loss without resistance training
• Expensive without coverage
• Newer — less long-term data than semaglutide
• Same thyroid precautions as GLP-1 class

Interaction rules that name Tirzepatide

From the app’s interaction data, filtered so no rule naming a compound this site does not publish appears. Not exhaustive, and not a safety clearance: a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The combination checker has the rest.

Questions people actually ask

Is tirzepatide simply a stronger semaglutide?

Not mechanistically. It acts at a receptor semaglutide does not touch, its backbone comes from a different hormone, and its half-life is shorter. The trial results are larger, and a head-to-head trial supports that ordering, but "stronger version of the same thing" is not an accurate description of the pharmacology.

How long before it is out of the system?

About five half-lives, so roughly three and a half to four weeks at the modelled figure. The half-life page has the curve and the accumulation arithmetic.

What happens to weight after stopping?

The withdrawal data for this class consistently shows substantial regain over the following year without continued treatment. That is a reason to think about the decision to start as a long-term one, and a reason to have the conversation about stopping with a prescriber rather than simply running out.

Why does the app record body composition rather than just weight?

Because at this rate of loss the composition of what is lost is the outcome that matters and weight cannot report it. A DEXA scan or a consistent bioimpedance measurement taken the same way each time gives you a trend; the scale gives you a number that two very different outcomes can produce.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.